International Stem Cell Stock

International Stem Cell ROA 2024

International Stem Cell ROA

-0.02

Ticker

ISCO

ISIN

US4603782016

In 2024, International Stem Cell's return on assets (ROA) was -0.02, a -62.3% increase from the -0.06 ROA in the previous year.

International Stem Cell Aktienanalyse

What does International Stem Cell do?

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding International Stem Cell's Return on Assets (ROA)

International Stem Cell's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing International Stem Cell's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider International Stem Cell's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in International Stem Cell’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about International Stem Cell stock

What is the Return on Assets (ROA) of International Stem Cell this year?

The Return on Assets (ROA) of International Stem Cell is -0.02 undefined this year.

What was the ROA of International Stem Cell compared to the previous year?

The ROA of International Stem Cell has increased by -62.3% compared to the previous year.

What consequences do high ROA have for investors of International Stem Cell?

A high ROA is advantageous for investors of International Stem Cell, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in International Stem Cell?

A low ROA can be unfavorable for investors of International Stem Cell as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of International Stem Cell affect the company?

An increase in ROA of International Stem Cell can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of International Stem Cell impact the company?

A reduction in the ROA of International Stem Cell can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of International Stem Cell?

Some factors that can influence the ROA of International Stem Cell include revenue, operating costs, asset structure, and industry average.

Why is the ROA of International Stem Cell important for investors?

The ROA of International Stem Cell is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can International Stem Cell take to improve ROA?

To improve ROA, International Stem Cell can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does International Stem Cell pay?

Over the past 12 months, International Stem Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, International Stem Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of International Stem Cell?

The current dividend yield of International Stem Cell is .

When does International Stem Cell pay dividends?

International Stem Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of International Stem Cell?

International Stem Cell paid dividends every year for the past 0 years.

What is the dividend of International Stem Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is International Stem Cell located?

International Stem Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von International Stem Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of International Stem Cell from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did International Stem Cell pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of International Stem Cell in the year 2023?

In the year 2023, International Stem Cell distributed 0 USD as dividends.

In which currency does International Stem Cell pay out the dividend?

The dividends of International Stem Cell are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von International Stem Cell

Our stock analysis for International Stem Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.